Results from the Phase II trial, presented at the European Society for Paediatric Infectious Diseases meeting in Austria, showed a series of three immunizations with MenB starting at two months of age produced a protective immune response.
ZURICH (Reuters) - Novartis AG's MenB vaccine showed potential to give broad protection to infants against meningococcal B infections in a mid-stage study, the Swiss drugmaker said on Wednesday.
Results from the Phase II trial, presented at the European Society for Paediatric Infectious Diseases meeting in Austria, showed a series of three immunizations with MenB starting at two months of age produced a protective immune response.
The meningococcal B strain causes 72 percent of meningitis infections in Europe.
(Reporting by Sam Cage, editing by Will Waterman)
!ADVERTISEMENT!
